10 Stocks Losing Big Amid Market Boom

Page 9 of 9

1. Replimune Group, Inc. (NASDAQ:REPL)

Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece after failing to clear regulatory challenges for its treatment candidate for melanoma.

In a statement, Replimune Group, Inc. (NASDAQ:REPL) said it met with the US Food and Drug Administration on Tuesday to discuss the agency’s complete response letter for its biologics license application for RP1, in combination with nivolumab, for the treatment of advanced melanoma.

However, the FDA provided a response, which Replimune Group, Inc. (NASDAQ:REPL) cannot figure out whether the drug can move forward under the FDA’s accelerated approval.

“The feedback from the melanoma community, including patients and physicians, clearly highlights the unmet need in advanced melanoma and the compelling risk-benefit profile of RP1 observed in the IGNYTE trial,” said Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel.

“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” he added.

While we acknowledge the potential of REPL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REPL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9